ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1669

High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study

Arthur Mageau1, Alois Helary2, Stephane Ruckly3, Andrey Strukov2, Thomas Papo1, Jean-Francois Timsit1 and Karim Sacre1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hopitaux de Paris, Paris, France, 3INSERM, Paris, France

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Infection, Outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Infection-related Rheumatic Disease

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Previous studies have shown that immune dysregulation associated with severe infection persists after discharge in two-thirds of surviving patients and is associated with worse long-term outcome. Hypothesizing that persistent immune dysregulation associated with sepsis may be involved in immune-mediated inflammatory diseases (IMIDs), we used a nationwide database to analyze the incidence of IMIDs after sepsis. We aim to analyze the incidence of IMIDs in patients who survived sepsis.

Methods: Comprehensive data on all exposed and non-exposed patients admitted to all French hospitals from January 2011 to November 2020 were collected from the national medical-administrative database, the PMSI (Programme de Médicalisation des Systèmes d’Information, Information system medicalization program). The PMSI provides a summary of diagnoses, procedures, and individual medical conditions at discharge from all French healthcare facilities. All data on adult patients admitted for sepsis between January to November 2020, in any of the French healthcare facilities were retrieved from the database. Exposure was sepsis requiring hospitalization. Sepsis was defined by the combination of at least one code of infection and one code referring to an organ failure diagnosis or procedure. Patients with a first sepsis (i.e. exposed) diagnosed in a French hospital in 2020 were randomly matched (ratio 1/1) with patients admitted during the same period for acute myocardial infarction (i.e. non-exposed). An exact matching procedure taking age ±2 years, gender, and comorbidities as matching variables was performed. The main outcome was a diagnosis of IMID based on specific ICD-10 codes during a 9-month follow up. Only patients with i) a first diagnosis of sepsis (exposed) or AMI (non-exposed) in 2020 and ii) no history of IMIDs reported in PMSI between January 1, 2010 and the index stay were included.

Results: In France, the incidence rate of IMIDs after a sepsis in 2020 – analyzed in 62,257 patients – was of 7,956 [95CI 7,392-8,520] per 100,000 patient-years. As compared to the non-exposed admitted population (Table 1), the IMID-free survival analysis showed an increased risk for IMIDs of 2.80 (HR; 95%CI [2.22-3.54]) starting from day 16 after admission (Figure 1). Risk of IMIDs following severe infection differed according to the nature of the autoimmune disease and were higher for immune thrombocytopenia (5.51 [1.97-15.4]), autoimmune hemolytic anemia (4.83 [1.45-16.1]) and ANCA associated vasculitis (4.66 [2.05-10.6]) (Figure 2).

Conclusion: Our study shows an intriguing and extremely high incidence of IMIDs among survivors of severe infections.

Supporting image 1

Table 1 Characteristics of the matched populations

Supporting image 2

Figure 1 Survival without IMIDs among matched populations

Supporting image 3

Figure 2 Risk for IMIDs onset after sepsis
IMIDs, immune-mediated inflammatory diseases; ITP, immune thrombocytopenia; AIHA, autoimmune hemolytic anemia; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSs, systemic sclerosis; RA, rheumatoid arthritis; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; IBD, inflammatory bowel disease; UC, ulcerative colitis; MS, multiple sclerosis.


Disclosures: A. Mageau: None; A. Helary: None; S. Ruckly: None; A. Strukov: None; T. Papo: None; J. Timsit: None; K. Sacre: None.

To cite this abstract in AMA style:

Mageau A, Helary A, Ruckly S, Strukov A, Papo T, Timsit J, Sacre K. High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/high-incidence-of-immune-mediated-inflammatory-diseases-in-sepsis-survivors-a-nationwide-exposed-non-exposed-epidemiological-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-incidence-of-immune-mediated-inflammatory-diseases-in-sepsis-survivors-a-nationwide-exposed-non-exposed-epidemiological-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology